|
⚲
|
| Keyboard |
| Avego Management LLC
✚
|
|
|---|---|
| CRD # | 310520 |
| SEC # | 801-120171 |
| CIK # | 0001886177 |
| AUM | 917.5 M (2026-03-31) |
| Employees | 16 (75% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-844-0030 |
| Address | 100 North Main Street Alpharetta, GA 30009 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5. Fees and Compensation The Adviser’s fees and compensation are described in each client’s Governing Documents. All of the Firm’s clients are expected to be “qualified purchasers” (as defined in Section 2(a)(51) of the Investment Company Act of 1940, as amended). Fees Generally Management Fees and Performance-Based Compensation. The management fee (the “Management Fee”) and performance-based compensation rates for the Funds are disclosed in each Fund’s Governing Documents. The Funds will pay the Adviser a Management Fee quarterly in advance based on Fund investor capital commitments with respect to one of the closed end funds, or the value of Fund investor capital accounts with respect to open end funds. Management Fees are prorated in the case of a partial calendar quarter. The Adviser may elect to reduce, otherwise modify or waive the Management Fee with respect to any of its affiliates, Fund investor, and the Adviser’s employees, in accordance with the Fund’s governing documents. An affiliate of the Adviser that serves as the general partner of a Fund (the “General Partner”) will be paid performance-based compensation by the Funds, which is compensation that is based on a share of capital gains on or capital appreciation of the assets of the Funds. Expenses Generally Investors in the Funds should carefully review the expense provisions in their applicable Fund Governing Documents for a complete description of such Fund’s expense practices. Each Fund is responsible for expenses incurred by it and related to its activities, including (as more fully defined in the Governing Documents) but not limited to: the Management Fee; Fund legal, compliance (including consultants’ fees), placement fees, risk management expenses (including software licensing and consultants’ fees), administrator (including, but not limited to, middle and back office services and software necessary for trade capture and portfolio management), audit and tax preparation (including third- party tax preparation), and accounting expenses (including third party accounting services and accounting software); all costs and expenses of any custodians, attorneys, accountants, auditors, tax advisors, brokers, agents, research related data providers, valuation experts or other advisors or professionals relating to the affairs of the Fund; organizational expenses; execution and order management system fees and expenses; investment expenses such as omissions, research-related fees and expenses (including Bloomberg and similar subscriptions and data services, expenses incurred in connection with multimedia, analytical, database, news or other third-party research services as well as related terminals for the delivery of such services, artificial intelligence tools used for research and research-related travel (including meals and lodging)); interest on margin accounts and other indebtedness; borrowing charges on securities sold short; custodial fees; bank service fees; all costs and expenses of any litigation, threatened litigation, indemnification or other extraordinary expenses or liabilities relating to the affairs of the Fund; Fund-related insurance costs (D&O and E&O insurance); independent master fund governance committee members’ fees and expenses; expenses of regulatory compliance (including compliance with AIFMD and AEOI), filings and reporting (including but not limited to Section 13, Section 16 and Form PF filings); all costs and expenses incurred in connection with complying with Anti-Money Laundering laws, “know your customer” laws and Foreign Account Tax Compliance Act (“FATCA”), including the fees and expenses of third-party service providers related to such compliance; costs and expenses incurred in connection with complying with provisions in Governing Documents and/or side letter agreements or similar agreements; unreimbursed costs and expenses incurred in connection with any transfer or proposed transfer or any default by a limited partner; expenses incurred in connection with the managed distribution of marketable securities; costs and expenses of any lenders and other financing sources, and principal and interest on, and fees and expenses arising out of, all borrowings made by the Fund, including, without limitation, the arranging, negotiating, structuring, entering into and amending thereof; directors’ fees (including the fees and expenses of independent master fund governance committee members directly related to their service as directors of the offshore fund); pricing service fees; all costs and expenses of winding-up and dissolving the Fund and any alternative investment vehicles; all expenses incurred in connection with any tax, audit, investigation, settlement, or review of the Fund; portfolio valuation expenses (including data feeds and third-party valuation agents); and any other expenses related to the purchase, sale or transmittal of Fund assets. Allocation of Expenses. Each Fund bears expenses as set forth in its respective Governing Documents. Common expenses may be incurred on behalf of the Funds. The Adviser would seek to allocate those common expenses among the Funds in a manner that would be fair and reasonable over time and in accordance with the relevant Governing Documents. As the allocation of expenses by the Adviser represents a conflict of interest, the Adviser has adopted an expense allocation policy that is designed to address this conflict. The Adviser may use various methods to allocate expenses among the Funds depending on the circumstances (e.g., pro rata based on assets under management, relative participation in the transaction related to the expense, general amount of trading activity etc.). The determination as to the method or methods used may be based on relative use of the product or service, the nature or source of the product or service, the relative benefits derived by each of the Funds from the product or service, or ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7. Types of Clients The Adviser’s clients consist of the Funds. Investors in the Funds are generally high net worth individuals and institutional investors that qualify as “accredited investors” (as defined in Rule 501 under the Securities Act of 1933, as amended) and qualified purchasers. The minimum initial investment in the Funds will be determined by the Adviser. The Adviser has waived such minimum and may, in its discretion, do so in the future under certain circumstances. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Velan Capital Opportunity Fund II LLC | [2026-03-30] | 2.4 M | 1.8 M |
| Filed 2025-03-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Velan Horizon Fund LP | 2025-03-28 | 9.1 M | |
| PE | Ahc-II AGR Partners LP | [2024-03-28] | 29.5 M | |
| Filed 2023-05-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Velan Capital SPV I LLC | [2024-03-28] | 5.5 M | 18.1 M |
| Filed 2023-06-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Avego Healthcare Capital Fund II LP | [2023-03-31] | 278.1 M | 366.4 M |
| Filed 2023-10-12 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $1,999,375 · Revenue Decline to Disclose | ||||
| HF | Velan Capital Master Fund LP | [2023-03-31] | 11.7 M | 256.1 M |
| Filed 2025-11-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Velan Capital Offshore Fund Ltd | [2023-03-31] | 11.7 M | |
| Filed 2025-11-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Avego Bioscience Capital LP | [2022-03-31] | 68.7 M | 92.4 M |
| Filed 2025-03-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Avego Healthcare Capital LP | [2020-12-16] | 109.4 M | 162.2 M |
| Filed 2024-11-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $122,900 · Revenue Decline to Disclose | ||||
| HF | Velan Capital Partners LP | [2020-12-16] | 11.7 M | 143.9 M |
| Filed 2025-11-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 9 | 917.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 9 | 917.5 |
| By Discretionary | ||
| Discretionary | 9 | 917.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 9 | 917.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 256.1 | |
| United States Persons | 661.4 | |
| Total | 9 | 917.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Thomas Vandervort | Executive Officer | 6 | 2 | |
| James Flexner | Executive Officer | 4 | 2 | |
| Velan Capital Investment Management LP | Executive Officer | 3 | 1 | |
| Velan Capital Holdings LLC | Executive Officer | 3 | 1 | |
| Balaji Venkataraman | Executive Officer | 2 | 1 | |
| Avego Management LLC | Executive Officer | 2 | 1 | |
| Avego Healthcare Capital GP II LLC | Director | 2 | 1 | |
| Kevin McNeill | Executive Officer | 2 | 1 | |
| Avego Bioscience Capital GP LLC | Executive Officer | 1 | 1 | |
| Avego Healthcare Capital Holdings LLC | Executive Officer | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001886177] | |
| 4 | [0001886177] | |
| SC 13G | [0001886177] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Avego Management LLC | Jasper Therapeutics Inc | [2021-10-04] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.3B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 2549009SHB59XHUX6731 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Amplitude Healthcare Acquisition Corp JSPR
Common Stock, par value $0.0001 per share
|
2024-02-08 | Buy | 350,000 | $12.95 | 4,532,500 |
| Comparable Firms | State | AUM |
|---|---|---|
|
EOS Management LP
✚
|
NY | 957.1 M |
|
ThornTree Capital Partners LP
✚
|
MA | 955.3 M |
|
HCSF Management LLC
✚
|
NY | 949.4 M |
|
Dalal Street LLC
✚
|
TX | 936.3 M |
|
Toscafund Asset Management LLP
✚
|
933.3 M | |
|
Sandalwood Securities Inc
✚
|
NJ | 930.2 M |
|
Extract Advisors LLC
✚
|
CA | 914.4 M |
|
Yorkville Advisors Global LP
✚
|
NJ | 900.0 M |
|
Bow Street LLC
✚
|
NY | 884.7 M |
|
Sandglass Capital Advisors LLC
✚
|
NY | 873.7 M |